摘要
心房颤动(房颤)是一种常见的心律失常疾病,发病率较高,且可引起多种并发症。其中,血栓栓塞性并发症是房颤致死、致残的最主要原因,而脑卒中是其最常见的表现类型,故预防脑卒中的发生成为房颤患者综合管理的重要内容。对于发生脑卒中风险增加的患者,合理应用抗凝药物有助于显著降低缺血性脑卒中的发生率。然而,在中国大多数房颤患者并未得到有效的抗凝治疗。且很多患者在抗凝期间发生脑卒中事件,严重影响了患者的健康及预后。目前,临床上已有多种新型口服抗凝药物(NOAC)供患者选择,且短期服用NOAC抗凝治疗对于房颤患者直流电复律是安全的。未来,NOAC能否将房颤患者的抗凝周期大大缩短,从而减少患者的脑卒中事件,需要进一步研究。
Atrial fibrillation（AF） is a common arrhythmia disease,with high incidence and multiple complications. The thromboembolic complications are the main reason of the mortality and morbidity, and the stroke is the most common type, therefore prevention of the stroke is the main content of the integrated management of AF patients. Rational use of anticoagu- lant drugs help to significantly reduce .the incidence of ischemic stroke, however, most AF patients have not received effec- tive anticoagulant therapy in China. Many patients have stroke events during anticoagulation, seriously damaging the health and prognosis. At present, there are a variety of new oral anticoagulant （NOAC） drugs for patients to choose, and short-term use of NOAC therapy for direct current cardioversion of AF patients is safe. Whether NOAC can shorten the anticoagulant cycle of AF patients so as to reduce the incidence of stroke in patients, still needs further study.
出处
《医学综述》
2017年第9期1821-1825,共5页
Medical Recapitulate
关键词
心房颤动
抗凝药物
脑卒中
血栓栓塞
Atrial fibrillation
Anticoagulant drugs
Stroke
Thromboembolic
